Yonghe Medical Group Co., Ltd. (2279) announced a turnaround in financial performance for the year ended 31 December 2025, projecting a net profit of at least RMB70.00 million, compared with a net loss of RMB226.60 million for the year ended 31 December 2024.

According to the announcement, this anticipated shift from loss to profit is largely driven by continuous improvements and refinements within the clinic network and internal systems. These measures include a more focused allocation of resources to high-potential clinics and further integration of the Group’s proprietary medical chain management system, boosting operational efficiency, quality control, and cost management. These initiatives are expected to raise the gross profit margin by around 5.50 to 6.50 percentage points from the prior year.

Additionally, ongoing restructuring of the management model and enhanced marketing strategies have reduced the overall expense ratio. The Group expects noticeable decreases in both selling and marketing, as well as general and administrative expenses ratios, ranging from 5.00% to 6.00% and 2.00% to 3.00% respectively compared with the previous year.

The final audited annual results are anticipated for release before the end of March 2026. The announcement advises shareholders and investors to exercise caution when dealing in the shares of Yonghe Medical Group Co., Ltd.